Structure-/disease-modifying agents for osteoarthritis.
OA is the most common articular disease. Age is its most notable risk factor. With the aging of the population of the developed world, there will be a growing need for better understanding of OA and for superior therapies. There is increasing appreciation for the role of inflammation in OA. There also is the realization that OA is not only a disease of cartilage, but of the entire joint. This has led to increasing interest in structure/disease modification as the goal in OA therapy. However, there are no universally proven structure-/ disease-modifying interventions.
Altman
Roy D
RD
Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. journals@royaltman.com
D000818:Animals; D002241:Carbohydrates / Q000627:therapeutic use; D019902:Chondrocytes / Q000637:transplantation; D016207:Cytokines / Q000627:therapeutic use; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D015316:Genetic Therapy; D006133:Growth Substances / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D033581:Stem Cell Transplantation; D013256:Steroids / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use
D002241:Carbohydrates; D016207:Cytokines; D004791:Enzyme Inhibitors; D006133:Growth Substances; D006728:Hormones; D013256:Steroids; D013754:Tetracyclines